BrainStorm Cell Therapeutics(BCLI)
NEW YORK, NYBiotechnology
Focus: BrainStorm Cell Therapeutics is a New York-based public biotech focused on autologous adult stem cell therapy, specifically MSC-NTF cell transplantation for neurodegenerative diseases. The company operates at small scale with minimal cash reserves and no reported revenue.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About BrainStorm Cell Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow BrainStorm Cell Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT04681118Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS
N/AHelp build intelligence for BrainStorm Cell Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.